Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients' treatment

被引：32
作者：
Onesti, Concetta Elisa [1 ,2 ,3 ]
Freres, Pierre [2 ]
Jerusalem, Guy [2 ,3 ]
机构：
[1] Univ Liege, GIGA Res Inst, Lab Human Genet, Liege, Belgium
[2] CHU Liege, Univ Hosp, Dept Med Oncol, Ave Hop 1, B-4000 Liege, Belgium
[3] Univ Liege, GIGA Res Inst, Lab Med Oncol, Liege, Belgium
来源：
JOURNAL OF THORACIC DISEASE | 2019年 / 11卷 / 01期
关键词：
IPILIMUMAB; NIVOLUMAB; DOCETAXEL;
D O I：
10.21037/jtd.2018.12.47
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：35 / 38
页数：4
相关论文
共 50 条
  • [31] Growth hormone associated with treatment efficacy of immune checkpoint inhibitors in gastric cancer patients
    Zhao, Yue
    Ji, Zhengzheng
    Li, Jiasong
    Zhang, Shasha
    Wu, Chensi
    Zhang, Ruixing
    Guo, Zhanjun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [32] Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non-small-cell lung cancer patients
    Zhang, Chufeng
    Wang, Jixin
    Sun, Zhongwen
    Cao, Yufeng
    Mu, Zhengshuai
    Ji, Xuming
    CANCER SCIENCE, 2021, 112 (08) : 3005 - 3017
  • [33] Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: a retrospective observational cohort study
    Gupta, Mehul
    Stukalin, Igor
    Meyers, Daniel E.
    Heng, Daniel Y. C.
    Monzon, Jose
    Cheng, Tina
    Navani, Vishal
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [34] Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy
    Reschke, Robin
    Gussek, Philipp
    Boldt, Andreas
    Sack, Ulrich
    Koehl, Ulrike
    Lordick, Florian
    Gora, Thomas
    Kreuz, Markus
    Reiche, Kristin
    Simon, Jan-Christoph
    Ziemer, Mirjana
    Kunz, Manfred
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (15)
  • [35] Clinical predictors of treatment efficacy and a prognostic nomogram in patients with lung adenocarcinoma receiving immune checkpoint inhibitors: a retrospective study
    Hu, Fang
    Peng, Jin
    Niu, Yanjie
    Mao, Xiaowei
    Zhao, Yizhuo
    Jiang, Liyan
    JOURNAL OF THORACIC DISEASE, 2022, 14 (10)
  • [36] Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies
    Yu, Yixuan
    Zhou, Yang
    Zhang, Xu
    Tan, Kexin
    Zheng, Jiabin
    Li, Jia
    Cui, Huijuan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [37] Multidisciplinary approach to treatment with immune checkpoint inhibitors in patients with HIV, tuberculosis, or underlying autoimmune diseases
    Aguilar-Company, Juan
    Lopez-Olivo, Maria A.
    Ruiz-Camps, Isabel
    FRONTIERS IN MEDICINE, 2022, 9
  • [38] Treatment-associated Fatigue in Cancer Patients Treated with Immune Checkpoint Inhibitors; a Systematic Review and Meta-analysis
    Abdel-Rahman, O.
    Helbling, D.
    Schmidt, J.
    Petrausch, U.
    Giryes, A.
    Mehrabi, A.
    Schob, O.
    Mannhart, M.
    Zidan, A.
    Oweira, H.
    CLINICAL ONCOLOGY, 2016, 28 (10) : E127 - E138
  • [39] Editorial: Management of Immune-Related Adverse Events for Patients Undergoing Treatment With Checkpoint Inhibitors
    Rapoport, Bernardo Leon
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [40] Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors
    Ando, Yosuke
    Hayashi, Takahiro
    Sugimoto, Reiko
    Nishibe, Seira
    Ito, Kaori
    Kawada, Kenji
    Ikeda, Yoshiaki
    Yamada, Shigeki
    Imaizumi, Kazuyoshi
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (04) : 1200 - 1206
12345